Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2020-08-01
|
| Series: | World Allergy Organization Journal |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1939455120301708 |
| _version_ | 1818304743344177152 |
|---|---|
| author | Anne K. Ellis Margarita Murrieta-Aguttes Sandy Furey Christopher Carlsten |
| author_facet | Anne K. Ellis Margarita Murrieta-Aguttes Sandy Furey Christopher Carlsten |
| author_sort | Anne K. Ellis |
| collection | DOAJ |
| first_indexed | 2024-12-13T06:15:33Z |
| format | Article |
| id | doaj.art-28518e3c00f24edcb7ff3ce250a5af37 |
| institution | Directory Open Access Journal |
| issn | 1939-4551 |
| language | English |
| last_indexed | 2024-12-13T06:15:33Z |
| publishDate | 2020-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | World Allergy Organization Journal |
| spelling | doaj.art-28518e3c00f24edcb7ff3ce250a5af372022-12-21T23:56:59ZengElsevierWorld Allergy Organization Journal1939-45512020-08-01138100267Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutantsAnne K. Ellis0Margarita Murrieta-Aguttes1Sandy Furey2Christopher Carlsten3Queen’s University - Kingston, Ontario, CanadaConsumer Health Care, Sanofi, Gentilly, FranceConsumer Health Care, Sanofi, Bridgewater, United StatesUniversity of British Columbia, Vancouver, Canadahttp://www.sciencedirect.com/science/article/pii/S1939455120301708 |
| spellingShingle | Anne K. Ellis Margarita Murrieta-Aguttes Sandy Furey Christopher Carlsten Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants World Allergy Organization Journal |
| title | Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants |
| title_full | Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants |
| title_fullStr | Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants |
| title_full_unstemmed | Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants |
| title_short | Phase 3, single-center, sequential and parallel-group, double-blind, randomized study evaluating the efficacy and safety of Fexofenadine Hydrochloride 180 mg (Allegra®/Telfast®) versus placebo in subjects suffering from seasonal Allergic Rhinitis with symptoms aggravated in presence of pollutants |
| title_sort | phase 3 single center sequential and parallel group double blind randomized study evaluating the efficacy and safety of fexofenadine hydrochloride 180 mg allegra r telfast r versus placebo in subjects suffering from seasonal allergic rhinitis with symptoms aggravated in presence of pollutants |
| url | http://www.sciencedirect.com/science/article/pii/S1939455120301708 |
| work_keys_str_mv | AT annekellis phase3singlecentersequentialandparallelgroupdoubleblindrandomizedstudyevaluatingtheefficacyandsafetyoffexofenadinehydrochloride180mgallegratelfastversusplaceboinsubjectssufferingfromseasonalallergicrhinitiswithsymptomsaggravatedinpresenceofpollutants AT margaritamurrietaaguttes phase3singlecentersequentialandparallelgroupdoubleblindrandomizedstudyevaluatingtheefficacyandsafetyoffexofenadinehydrochloride180mgallegratelfastversusplaceboinsubjectssufferingfromseasonalallergicrhinitiswithsymptomsaggravatedinpresenceofpollutants AT sandyfurey phase3singlecentersequentialandparallelgroupdoubleblindrandomizedstudyevaluatingtheefficacyandsafetyoffexofenadinehydrochloride180mgallegratelfastversusplaceboinsubjectssufferingfromseasonalallergicrhinitiswithsymptomsaggravatedinpresenceofpollutants AT christophercarlsten phase3singlecentersequentialandparallelgroupdoubleblindrandomizedstudyevaluatingtheefficacyandsafetyoffexofenadinehydrochloride180mgallegratelfastversusplaceboinsubjectssufferingfromseasonalallergicrhinitiswithsymptomsaggravatedinpresenceofpollutants |